Stem Cell Assay Market Analysis With Key Players, Applications, Trends and Forecast To 2026 – Instant Tech News

Stem Cell Assay Market Overview:

Verified Market Research adds new research report Stem Cell Assay Market Development Overview 2020, The report includes an in-depth analysis of the toggle switch market, taking into account market dynamics, segmentation, geographic expansion, competitive landscape and some other key issues. The market analysts who prepared the report have thoroughly examined the toggle switch market and provided reliable and accurate data. They understand the needs of the industry and customers, which makes it easier for them to focus on the problems that end users have been looking for. The research report provides an analysis of an assessment of existing and future trends in which players can invest. It also includes an assessment of the players financial perspectives and the nature of the competition.

Global Stem Cell Assay market was valued at USD 536.53million in 2016 and is projected to reach USD 2858.95millionby 2025, growing at a CAGR of 20.43% from 2017 to 2025.

Request a Report Brochure @ https://www.verifiedmarketresearch.com/download-sample/?rid=24266&utm_source=ITN&utm_medium=005

Top 10 Companies in the Stem Cell Assay Market Research Report:

Competitive Landscape

The competitive landscape is a must-have information for the marketplayersto withstand the competition present in theglobal Stem Cell Assay market. This further helps the market participants to develop effective strategies to optimize their market positions. Moreover, the competitive analysis helps them to determine potential advantages as well as barriers within the global Stem Cell Assay market. This way, they can monitor how their competitors are implementing various strategies including pricing, marketing, and distribution.

The report analyses thecurrent trends, growth opportunities, competitive pricing, restraining factors, and boosters that may have an impact on the overall dynamics of the global Stem Cell Assay market. The report analytically studies the microeconomic and macroeconomic factors affecting the global Stem Cell Assay market growth. New and emerging technologies that may influence the global Stem Cell Assay market growth are also being studied in the report.

Global Stem Cell Assay Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the global Stem Cell Assay market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the global Stem Cell Assay market.

Regions Covered by the global market for Stem Cell Assay :

Middle East and Africa (GCC countries and Egypt)North America (USA, Mexico and Canada)South America (Brazil, etc.)Europe (Turkey, Germany, Russia, Great Britain, Italy, France etc.)Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=ITN&utm_medium=005

The study objectives are:

Important Questions Answered in this Report:-

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=ITN&utm_medium=005

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Assay Market Size, Stem Cell Assay Market Growth, Stem Cell Assay Market Forecast, Stem Cell Assay Market Analysis, Stem Cell Assay Market Trends, Stem Cell Assay Market

Read the rest here:
Stem Cell Assay Market Analysis With Key Players, Applications, Trends and Forecast To 2026 - Instant Tech News

Stem Cell Alopecia Treatment Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 – Instant Tech News

New Jersey, United States, The report titled, Stem Cell Alopecia Treatment Market Size and Forecast 2026 in Verified Market Research offers its latest report on the global Stem Cell Alopecia Treatment market that includes comprehensive analysis on a range of subjects like competition, segmentation, regional expansion, and market dynamics. The report sheds light on future trends, key opportunities, top regions, leading segments, the competitive landscape, and several other aspects of the Stem Cell Alopecia Treatment market. Get access to crucial market information. Market players can use the report back to peep into the longer term of the worldwide Stem Cell Alopecia Treatment market and convey important changes to their operating style and marketing tactics to realize sustained growth.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=ITN&utm_medium=002

Top 10 Companies in the Global Stem Cell Alopecia Treatment Market Research Report:

Global Stem Cell Alopecia Treatment Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Stem Cell Alopecia Treatment Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Stem Cell Alopecia Treatment Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Stem Cell Alopecia Treatment Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Stem Cell Alopecia Treatment Market is segmented on the basis of product type, applications, and its end users.

Global Stem Cell Alopecia Treatment Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=ITN&utm_medium=002

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report Complete Report is Available @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=ITN&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

Read the original here:
Stem Cell Alopecia Treatment Market 2020 Booming by Size, Revenue, Trend and Top Companies 2026 - Instant Tech News

MicroCures Announces Material Transfer Agreement with Henry M. Jackson Foundation for the Advancement of Military Medicine to Support Preclinical…

NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- MicroCures, a biopharmaceutical company developing novel therapeutics that harness the bodys innate regenerative mechanisms to accelerate tissue repair, today announced that it has entered into a material transfer agreement (MTA) with the Henry M. Jackson Foundation (HJF) for the Advancement of Military Medicine. Under terms of the agreement, United States Department of Defense researchers will conduct a preclinical study of siFi2, MicroCures lead product candidate, in animal models of spinal cord injury. siFi2, a small interfering RNA (siRNA) therapeutic that can be applied topically, is designed to enhance recovery after trauma.

Researchers, led by Kimberly Byrnes, Ph.D. of Uniformed Services University of the Health Sciences, will evaluate the potential of siFi2 treatment to drive axon regeneration and functional recovery in a rat model of spinal cord injury. As part of this study, multiple siFi2 formulations will be evaluated in order to assist in the identification of a lead formulation to be advanced into clinical development.

MicroCures technology is based on foundational scientific research at Albert Einstein College of Medicine regarding the fundamental role that cell movement plays as a driver of the bodys innate capacity to repair tissue, nerves, and organs. The company has shown that complex and dynamic networks of microtubules within cells crucially control cell migration, and that this cell movement can be reliably modulated to achieve a range of therapeutic benefits. Based on these findings, the company has established a first-of-its-kind proprietary platform to create siRNA-based therapeutics capable of precisely controlling the speed and direction of cell movement by selectively silencing microtubule regulatory proteins (MRPs).

The company has developed a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures technology directs and enhances the bodys inherent healing processes through local, temporary modulation of cell motility. siFi2 is a topical siRNA-based treatment designed to silence the activity of Fidgetin-Like 2 (FL2), a fundamental MRP, within an area of wounded tissue or nerve. In doing so, the therapy temporarily triggers accelerated movement of cells essential for repair into an injury area. Importantly, based on its topical administration, siFi2 can be applied early in the treatment process as a supplement to current standard of care.

The U.S. Department of Defense continues to be a valued and trusted partner for MicroCures as we work to advance research of siFi2 with the goal of ultimately delivering transformative treatments to patients with significant unmet medical needs, said David Sharp, Ph.D., co-founder and chief science officer of MicroCures. With a focus in the area of spinal cord injury, this MTA further demonstrates the broad applicability of our technology platform to a range of therapeutic indications. We look forward to collaborating with Dr. Byrnes and her team at Uniformed Services University of the Health Sciences to continue the advancement of this promising program.

Previously conducted research in a rat model of spinal cord injury has demonstrated that treatment with siFi2 allowed axon growth to occur through the inhibitory barriers that typically appear and prevent healing at the site of injury. Conversely, study results failed to demonstrate similar axon growth through these inhibitory barriers for animals administered a siRNA control treatment. Additional preclinical findings have demonstrated functional improvement in rats with spinal cord injury following treatment with siFi2. This was evidenced by significantly improved hind limb locomotor function in siFi2-treated animals as compared to control subjects at Day 5 (p < 0.05) and Day 7 (p < 0.01).

About MicroCures

MicroCures develops biopharmaceuticals that harness innate cellular mechanisms within the body to precisely control the rate and direction of cell migration, offering the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications.

MicroCures has developed a broad pipeline of novel therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. The companys lead therapeutic candidate, siFi2, targets excisional wound healing, a multi-billion dollar market inadequately served by current treatments. Additional applications for the companys cell migration accelerator technology include dermal burn repair, corneal burn repair, cavernous nerve repair/regeneration, spinal cord repair/regeneration, and cardiac tissue repair. Cell migration decelerator applications include combatting cancer metastases and fibrosis. The company protects its unique platform and proprietary therapeutic programs with a robust intellectual property portfolio including eight issued or allowed patents, as well as eight pending patent applications.

For more information please visit: http://www.microcures.com

Contact:

Vida Strategic Partners (On behalf of MicroCures)

Stephanie Diaz (investors)415-675-7401sdiaz@vidasp.com

Tim Brons (media)415-675-7402tbrons@vidasp.com

Originally posted here:
MicroCures Announces Material Transfer Agreement with Henry M. Jackson Foundation for the Advancement of Military Medicine to Support Preclinical...

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market by Key Players, Deployment Type, Applications, Vertical, and Region-Global 2026…

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market report is designed by detailed investigation procedure to collect all the necessary data. This report contains the brief profile of leading players in the industry along with their future plans and current developments. Further, report considers the revenue generated from the market analysis and opportunity analysis to estimate the market size. The report initiates with the basic market outlook and structure along with forecast of the various segments and sub-segments.

You Can Get a Sample Copy of this Report at https://www.orianresearch.com/request-sample/1479129

What You Can Expect From Our Report:

Purchase Directly @ https://www.orianresearch.com/checkout/1479129

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market research report involves emphasis on historic along with forecast revenue of the market segments and anticipated growth rates. The chief elements driving and impacting growth market data and analytics are derived from a combination of primary and secondary sources.

The key players covered in this study, Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

No of Pages: 97

The scope of the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Report:

Market segment by Type, the product can be split intoPlatelet Rich Plasma InjectionsStem Cell TherapyMarket segment by Application, split intoDermatology ClinicsHospitals

Important Aspects of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Report:

Why To Select This Report:

Complete analysis on market dynamics, market status and competitive Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies view is offered.

Forecast Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry trends will present the market drivers, constraints and growth opportunities.

The five-year forecast view shows how the market is expected to grow in coming years.

All vital Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry verticals are presented in this study like Product Type, Applications and Geographical Regions.

Table of Contents

1 Study Coverage

2 Executive Summary

3 Breakdown Data by Manufacturers

4 Breakdown Data by Type

4.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Sales by Type

4.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue by Type

4.3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Price by Type

5 Breakdown Data by Application

5.1 Overview

5.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application

6 North America

7 Europe

8 Asia Pacific

9 Central & South America

10 Middle East and Africa

11 Company Profiles

12 Future Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

14 Value Chain and Sales Channels Analysis

15 Research Findings and Conclusion

16 Appendix

Customization Service of the Report:-

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Read the rest here:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market by Key Players, Deployment Type, Applications, Vertical, and Region-Global 2026...

Building a ‘doomsday vault’ to save the kangaroo and koala from extinction – CNET

The road into Batlow is littered with the dead.

In the smoky, gray haze of the morning, it's hard to make out exactly what Matt Roberts' camera is capturing. Roberts, a photojournalist with the Australian Broadcasting Corporation, keeps his lens focused on the road as he rolls into the fire-ravaged town 55 miles west of Canberra, Australia's capital. At the asphalt's edge, blackened livestock carcasses lie motionless.

The grim scene, widely shared on social media, is emblematic of the impact the 2019-20 bushfire season has had on Australia's animal life. Some estimates suggest "many, many billions" of animals have been killed, populations of endemic insects could be crippled and, as ash washes into riverways, marine life will be severely impacted. The scale of the bushfires is so massive, scientists are unlikely to know the impact on wildlife for many years.

But even before bushfires roared across the country, Australia's unique native animals were in a dire fight for survival. Habitat destruction, invasive species, hunting and climate change have conspired against them. Populations of native fauna are plummeting or disappearing altogether, leaving Australia with an unenviable record: It has the highest rate of mammal extinctions in the world.

A large share of Australia's extinctions have involved marsupials -- the class of mammals that includes the nation's iconic kangaroos, wallabies, koalas and wombats. A century ago, the Tasmanian tiger still padded quietly through Australia's forests. The desert rat-kangaroo hopped across the clay pans of the outback, sheltering from the sun in dug-out nests.

Now they're gone.

Australia's 2019-20 bushfire season has been devastating for wildlife.

In a search for answers to the extinction crisis, researchers are turning to one lesser-known species, small enough to fit in the palm of your hand: the fat-tailed dunnart. The carnivorous mouse-like marsupial, no bigger than a golf ball and about as heavy as a toothbrush, has a tiny snout, dark, bulbous eyes and, unsurprisingly, a fat tail. It's Baby Yoda levels of adorable -- and it may be just as influential.

Mapping the dunnart's genome could help this little animal become the marsupial equivalent of the lab mouse -- a model organism scientists use to better understand biological processes, manipulate genes and test new approaches to treating disease. The ambitious project, driven by marsupial geneticist Andrew Pask and his team at the University of Melbourne over the last two years, will see scientists take advantage of incredible feats of genetic engineering, reprogramming cells at will.

It could even aid the creation of a frozen Noah's Ark of samples: a doomsday vault of marsupial cells, suspended in time, to preserve genetic diversity and help prevent further decline, bringing species back from the brink of extinction.

If that sounds far-fetched, it isn't. In fact, it's already happening.

Creating a reliable marsupial model organism is a long-held dream for Australian geneticists, stretching back to research pioneered by famed statistician Ronald Fisher in the mid-20th century. To understand why the model is so important, we need to look at the lab mouse, a staple of science laboratories for centuries.

"A lot of what we know about how genes work, and how genes work with each other, comes from the mouse," says Jenny Graves, a geneticist at La Trobe University in Victoria, Australia, who has worked with marsupials for five decades.

The mouse is an indispensable model organism that shares many genetic similarities with humans. It has been key in understanding basic human biology, testing new medicines and unraveling the mysteries of how our brains work. Mice form such a critical part of the scientific endeavor because they breed quickly, have large litters, and are cheap to house, feed and maintain.

The lab mouse has been indispensable in understanding physiology, biology and genetics.

In the 1970s, scientists developed a method to insert new genes into mice. After a decade of refinement, these genetically modified mice (known as "transgenic mice") provided novel ways to study how genes function. You could add a gene, turning its expression up to 11, or delete a gene entirely, shutting it off. Scientists had a powerful tool to discover which genes performed the critical work in reproduction, development and maturation.

The same capability does not exist for marsupials. "At the moment, we don't have any way of manipulating genes in a devil or a kangaroo or a possum," says Graves. Without this capability, it's difficult to answer more pointed questions about marsupial genes and how they compare with mammal genes, like those of mice and humans.

So far, two marsupial species -- the Tammar wallaby and the American opossum -- have been front and center of research efforts to create a reliable model organism, but they both pose problems. The wallaby breeds slowly, with only one baby every 18 months, and it requires vast swaths of land to maintain.

The short-tailed opossum might prove an even more complicated case. Pask, the marsupial geneticist, says the small South American marsupial is prone to eating its young, and breeding requires researchers to sift through hours of video footage, looking for who impregnated whom. Pask also makes a patriotic jab ("they're American so we don't like them") and says their differences from Australian marsupials make them less useful for the problems Australian species face.

But the dunnart boasts all the features that make the mouse such an attractive organism for study: It is small and easy to house, breeds well in captivity and has large litters.

"Our little guys are just like having a mouse basically, except they have a pouch," Pask says.

Pask (front) and Frankenberg inspect some of their dunnarts at the University of Melbourne.

A stern warning precedes my first meeting with Pask's colony of fat-tailed dunnarts.

"It smells like shit," he says. "They shit everywhere."

I quickly discover he's right. Upon entering the colony's dwellings on the third floor of the University of Melbourne's utilitarian BioSciences building, you're punched in the face by a musty, fecal smell.

Pask, a laid-back researcher whose face is almost permanently fixed with a smile, and one of his colleagues, researcher Stephen Frankenberg, appear unfazed by the odor. They've adapted to it. Inside the small room that houses the colony, storage-box-cages are stacked three shelves high. They're filled with upturned egg cartons and empty buckets, which work as makeshift nests for the critters to hide in.

Andrew Pask

Frankenberg reaches in without hesitation and plucks one from a cage -- nameless but numbered "29" -- and it hides in his enclosed fist before peeking out of the gap between his thumb and forefinger, snout pulsing. As I watch Frankenberg cradle it, the dunnart seems curious, and Pask warns me it's more than agile enough to manufacture a great escape.

In the wild, fat-tailed dunnarts are just as inquisitive and fleet-footed. Their range extends across most of southern and central Australia, and the most recent assessment of their population numbers shows they aren't suffering population declines in the same way many of Australia's bigger marsupial species are.

Move over, Baby Yoda.

As I watch 29 scamper up Frankenberg's arm, the physical similarities between it and a mouse are obvious. Pask explains that the dunnart's DNA is much more closely related to the Tasmanian devil, an endangered cat-sized carnivore native to Australia, than the mouse. But from a research perspective, Pask notes the similarities between mouse and dunnart run deep -- and that's why it's such an important critter.

"The dunnart is going to be our marsupial workhorse like the mouse is for placental mammals," Pask says.

For that to happen, Pask's team has to perfect an incredible feat of genetic engineering: They have to learn how to reprogram its cells.

To do so, they collect skin cells from the dunnart's ear or footpad and drop them in a flask where scientists can introduce new genes into the skin cell. The introduced genes are able to trick the adult cell, convincing it to become a "younger," specialized cell with almost unlimited potential.

The reprogrammed cells are known as "induced pluripotent stem cells," or iPS cells, and since Japanese scientists unraveled how to perform this incredible feat in 2006, they have proven to be indispensable for researchers because they can become any cell in the body.

"You can grow them in culture and put different sorts of differentiation factors on them and see if they can turn into nerve cells, muscle cells, brain cells, blood vessels," Pask explains. That means these special cells could even be programmed to become a sperm or an egg, in turn allowing embryos to be made.

Implanting the embryo in a surrogate mother could create a whole animal.

It took about 15 minutes to get this dunnart to sit still.

Although such a technological leap has been made in mice, it's still a long way from fruition for marsupials. At present, only the Tasmanian devil has had iPS cells created from skin, and no sperm or egg cells were produced.

Pask's team has been able to dupe the dunnart's cells into reverting to stem cells -- and they've even made some slight genetic tweaks in the lab. But that's just the first step.

He believes there are likely to be small differences between species, but if the methodology remains consistent and reproducible in other marsupials, scientists could begin to create iPS cells from Australia's array of unique fauna. They could even sample skin cells from wild marsupials and reprogram those.

Doing so would be indispensable in the creation of a biobank, where the cells would be frozen down to -196 degrees Celsius (-273F) and stored until they're needed. It would act as a safeguard -- a backup copy of genetic material that could, in some distant future, be used to bring species back from the edge of oblivion, helping repopulate them and restoring their genetic diversity.

Underneath San Diego Zoo's Beckman Center for Conservation Research lies the Frozen Zoo, a repository of test tubes containing the genetic material of over 10,000 species. Stacked in towers and chilled inside giant metal vats, the tubes contain the DNA of threatened species from around the world, suspended in time.

It's the largest wildlife biobank in the world.

"Our goal is to opportunistically collect cells ... on multiple individuals of as many species as we can, to provide a vast genetic resource for research and conservation efforts," explains Marlys Houck, curator at the Frozen Zoo.

The Zoo's efforts to save the northern white rhino from extinction have been well publicized. Other research groups have been able to create a northern white rhino embryo in the lab, combining eggs of the last two remaining females with frozen sperm from departed males. Scientists propose implanting those embryos in a surrogate mother of a closely related species, the southern white rhino, to help drag the species back from the edge of oblivion.

For the better part of a decade, conservationists have been focused on this goal, and now their work is paying off: In the "coming months," the lab-created northern white rhino embryo will be implanted in a surrogate.

Sudan, the last male northern white rhinoceros, was euthanized in 2018.

Marisa Korody, a conservation geneticist at the Frozen Zoo, stresses that this type of intervention was really the last hope for the rhino, a species whose population had already diminished to just eight individuals a decade ago.

"We only turn to these methods when more traditional conservation methods have failed," she says.

In Australia, researchers are telling whoever will listen that traditional conservation methods are failing.

"We've been saying for decades and decades, many of our species are on a slippery slope," says John Rodger, a marsupial conservationist at the University of Newcastle, Australia, and CEO of the Fauna Research Alliance, which has long advocated for the banking of genetic material of species in Australia and New Zealand.

In October, 240 of Australia's top scientists delivered a letter to the government detailing the country's woeful record on protecting species, citing the 1,800 plants and animals in danger of extinction, and the "weak" environmental laws which have been ineffective at keeping Australian fauna alive.

Institutions around Australia, such as Taronga Zoo and Monash University, have been biobanking samples since the '90s, reliant on philanthropic donations to stay online, but researchers say this is not enough. For at least a decade, they've been calling for the establishment of a national biobank to support Australia's threatened species.

John Rodger

"Our real problem in Australia ... is underinvestment," Rodger says. "You've got to accept this is not a short-term investment."

The current government installed a threatened-species commissioner in 2017 and committed $255 million ($171 million in US dollars) in funding to improve the prospects of 20 mammal species by 2020. In the most recent progress report, released in 2019, only eight of those 20 were identified as having an "improved trajectory," meaning populations were either increasing faster or declining slower compared to 2015.

A spokesperson for the commissioner outlined the $50 million investment to support immediate work to protect wildlife following the bushfires, speaking to monitoring programs, establishment of "insurance populations" and feral cat traps. No future strategies regarding biobanking were referenced.

Researchers believe we need to act now to preserve iconic Australian species like the koala.

In the wake of the catastrophic bushfire season and the challenges posed by climate change, Australia's extinction crisis is again in the spotlight. Koalas are plastered over social media with charred noses and bandaged skin. On the front page of newspapers, kangaroos bound in front of towering walls of flame.

Houck notes that San Diego's Frozen Zoo currently stores cell lines "from nearly 30 marsupial species, including koala, Tasmanian devil and kangaroo," but that's only one-tenth of the known marsupial species living in Australia today.

"Nobody in the world is seriously working on marsupials but us," Rodger says. "We've got a huge interest in maintaining these guys for tourism, national icons... you name it."

There's a creeping sense of dread in the researchers I talk to that perhaps we've passed a tipping point, not just in Australia, but across the world. "We are losing species at an alarming rate," says Korody from the Frozen Zoo. "Some species are going extinct before we even know they are there."

With such high stakes, Pask and his dunnarts are in a race against time. Perfecting the techniques to genetically engineer the tiny marsupial's cells will help enable the preservation of all marsupial species for generations to come, future-proofing them against natural disasters, disease, land-clearing and threats we may not even be able to predict right now.

Pask reasons "we owe it" to marsupials to develop these tools and, at the very least, biobank their cells if we can't prevent extinction. "We really should be investing in this stuff now," he says. He's optimistic.

In some distant future, years from now, a bundle of frozen stem cells might just bring the koala or the kangaroo back from the brink of extinction.

And for that, we'll have the dunnart to thank.

Originally published Feb. 18, 5 a.m. PT.

Continued here:
Building a 'doomsday vault' to save the kangaroo and koala from extinction - CNET

Lawyer thought her tiredness was down to jet lag until she visited doctor – Mirror Online

A high-flying lawyer who thought she had jet lag after relocating to Hong Kong was actually suffering from an aggressive form of leukaemia.

Alexandra Simpson has spoken out about her cancer battle to encourage others to be mindful of their bodies and to ask their doctors for a blood test if they are worried about any persistent symptoms.

The 26-year-old from Llandudno, north Wales, is now in remission but, to lessen the risk of relapsing she is also having a stem cell transplant, having started a week of chemotherapy before having the procedure on February 21.

Alexandra was 25 when she started suffering from fatigue and blamed her tiredness on her massive career move from London to Hong Kong.

It was only when mysterious bruises popped up all over her body that Alexandra saw a doctor, reports WalesOnline.

Still believing she had the world at her feet, Alexandra relived her horror when she received her blood test results the following day, saying: "The doctor told me, Its not great news, today'."

Alexandra had acute lymphoblastic leukaemia (ALL) cancer of the white blood cells- and her life was under threat so she needed treatment immediately.

The doctor told me hed booked an appointment with a specialist for me at midday, then wished me luck, she said.

I left in floods of tears. It was the middle of the night back home, and I knew I had to tell my mum, but I wanted to give her a few more minutes of not knowing her child had cancer.

I wandered around the city, which was still quite unfamiliar to me, with no idea where to go, she continued.

Eventually, I called home and Mum just kept saying, No.

She saw me as this strong, healthy girl it was shocking that cancer could suddenly hit me so aggressively.

You sometimes imagine how it may feel to be told you have cancer.

"On TV, people always seem to go numb their hearing fades and the room around them swirls. I actually became hyper-aware. I still remember every word the doctor said to me, even now.

And while its been incredibly difficult both for me and the people that have walked alongside me, seeing the horror of it all I wouldnt undo any of what Ive been through.

She added: Before, I think I was a little lost, almost sleepwalking through my twenties.

"But now, Ive learnt to appreciate the little things all those beautiful moments youd otherwise take for granted and have a purpose and a passion in raising awareness of leukaemia.

Doctors now believe that cancerous cells first started to invade Alexandra around January 2019, when she had seen a GP in London because she was feeling rundown and had concernes she was anaemic.

Working in a busy law firm, when she had noticed dark circles around her eyes, she assumed it was her fast-paced lifestyle taking its toll rather than anything more sinister.

She said: I almost got used to having very little energy. I was working long hours and still managing to get myself to the gym three times a week, so I didnt think it was anything overly worrying.

I blamed city life. I kept telling myself Id be moving to Hong Kong soon and would feel better in a new place, with a bit of sunshine.

Alexandras doctor agreed she could be anaemic so suggested she eat more red meat, or try an iron supplement to get her levels up.

Assuming that would be the end of it, Alexandra turned her thoughts to her big move in early March 2019.

When her fatigue did not lift, she said: I kept telling myself Id just moved around the world and that feeling tired was natural but I just wasnt bouncing back from the jetlag.

As I became more comfortable with the new friends I was making out there, they remarked that I still looked pale, despite being in the sweltering heat every day.

Agreeing she could be anaemic, Alexandras doctor suggested she eat more red meat, or try an iron supplement to get her levels up.

]]

So, assuming that would be the end of it, she turned her thoughts to her big move in early March 2019.

When her fatigue did not lift, she said: I kept telling myself Id just moved around the world and that feeling tired was natural but I just wasnt bouncing back from the jetlag.

As I became more comfortable with the new friends I was making out there, they remarked that I still looked pale, despite being in the sweltering heat every day.

It was at the end of March when Alexandra banged her leg getting out of the bath one day and noticed a dramatic bruise forming within minutes that she thought something sinister was happening.

She continued: It kept developing, getting larger and larger, to the point where I was embarrassed to show it, as I could feel people staring, wondering what Id done.

That seemed to almost trigger something in my body and, before long, clusters of bruises sprang up all over, with no explanation as to where theyd come from.

Alexandra looked up her symptoms online and was shocked when almost all of them pointed towards leukaemia.

So, using healthcare benefits she had through work, in April she booked a private appointment to see a doctor, who gave her a blood test with the results back the next morning.

Id just sat down at my desk when my phone started to ring, recalled Alexandra.

I dont think the receptionist even said hello. She just asked, Where are you? and told me to come in right away.

The urgency in her voice was really worrying. When I got there, I was trying to analyse the doctors face. I knew that something serious was going on, as he couldnt quite look at me. Then he told me I had leukaemia.

After wandering around the city and phoning her mum, feeling shaken and disorientated, Alexandra returned to her office and broke the news to her colleagues.

A colleague came over to ask if I was okay, as I was visibly upset. I think she assumed itd be a break-up, or homesickness a more normal problem for a 20-something who had moved across the world to be facing, she said.

When I told her, I watched the colour drain from her face. She sat with me and we talked it all over then, bizarrely, I actually wanted to do a bit of work while I waited for my midday appointment. My colleagues thought I was bonkers, but I needed a distraction.

When Alexandra she saw the specialist later that day she realised how gravely ill she was.

She recalled: He told me I wasnt well enough to fly back to the UK, and I needed to go straight to hospital.

I said, 'Okay, Ill just go home to get some things'. But he told me no, that if I somehow fell or knocked myself on the way, that my blood didnt have enough platelets to form clots, so I could bleed to death.

She continued: "He said, 'You need to go to hospital right now, and just to warn you, youll be there for at least a month'. He was good at keeping me calm, but also making me realise how much danger I was in.

Admitted to hospital, Alexandra was given a bone marrow biopsy, which confirmed her official diagnosis.

According to the charity Leukaemia Care, ALL is a rapidly progressing form of the disease, with almost 350 cases a year diagnosed in UK adults.

Symptoms can include fatigue, fever, frequent infections, unusual bleeding, unexplained weight loss and small purple spots on the skin known as purpura.

Three days after her diagnosis, Alexandra began the first of four gruelling cycles of chemotherapy.

It all happened so quickly, I didnt really have time to consider what I was about to put my body through. I was just focused on getting the cancerous cells eliminated, she said.

"When I look back at that part of everything, it doesnt feel like my life. Its like Im looking at another girl thinking, 'Poor her, shes been through so much'.

As well as the obvious side-effects, like losing my hair and having to deal with everybody staring at me, knowing I was sick, there were all these other little ways it impacted me.

For example, my fitness level plummeted to the point where Id have to take a rest when walking upstairs.

It was like being locked out of my own life. The chemo made me sicker than the cancer, in a way but I knew it was the cure, and I had to keep going.

By May, Alexandra had stabilised enough to fly home, where she continued the rest of her chemotherapy at Manchesters Christie Hospital, finishing in September 2019.

Later that month, she began immunotherapy, where the bodys own immune system is used to fight off cancerous cells.

She said: The form I had targets a specific antigen in the leukemic cells, and uses my own immune system to kill the cancer. The drug I take is slowly infused over a 28-day period, so I carry around a pump that delivers a very small dose every minute.

Now in remission, Alexandra described how her journey has made her re-evaluate life, and find value in small things she may have once taken for granted.

She said: I know now I wasnt prioritising the right things, like chasing that deal at work, or buying the latest designer handbag. Those things do have a place in life, and they are important, but they arent the be all and end all.

Now, things like sitting around the table with my family laughing, or feeling the sun on my neck in the garden those are the moments that mean the most.

For a long time, I put what happened in a box, only to be opened at certain times.

Now Ive gone from being obsessed that nobody would know to look at me what Ive been through, to being proud of my scars.

Ive worked through that denial to find a place of peace. Ive found my cause in life and am so proud to be a part of the cancer community.

Urging people to be mindful of the bodies, she said: You know your body better than anybody, so if you feel something has changed however minor then ask your doctor for a blood test, she said.

The likelihood is it will be something much more minor than leukaemia, but if it is serious, its important to catch it early. Going through this has completely changed my mindset, and Im so glad to still be here to appreciate the little things that make life so beautiful.

View post:
Lawyer thought her tiredness was down to jet lag until she visited doctor - Mirror Online

News Royal Oak native meets woman she saved with vital stem cell donation Jenn Schanz 11 – WXYZ

When you see Kelly Schneider and Alex Barr together, you'd think they go way back; they laugh at the same moments, seem to have inside jokes, and generally send off a vibe that they're old friends.

"Our families are both Middle Eastern, so we just have this connection. Weve just been gabbing and eating like we know each other," Schneider told Action News at her mother's house in Bloomfield Hills on Sunday.

It's where Barr and her mother came from the Boston area to meet Schneider and her family or the very first time in person, and to say thank you, since sharing something pretty personal back in August of 2018.

"I mean, she kind of is morphing into me now that she has my DNA. Thats how this works, right?" Schneider joked.

About a year earlier, in the summer of 2017 Barr, then in graduate school in the Boston area, learned she had Leukemia for the second time.

"It was just unreal. Like I couldnt even process it," Barr told Action News.

Barr didn't know it then, but Schneider had already signed up with Be The Match, and a national bone marrow registry, when she learned a close friend was diagnosed with cancer.

"We went and got tested and we donated blood. And unfortunately she did not survive. But after 4 or 5 months after she passed away, I got a call from Be The Match.

That call was on behalf of Barr, hoping Schneider might be willing to donate life-saving bone marrow.

Soon after, Schneider was getting treatment to donate stem cells from her bone marrow, to save Barr's life, who was still a stranger at the time.

All Schneider knew then was that her donation was going to help a 24-year-old from Michigan.

"How could you not? If someone needs it?" She said.

"When you hear bone marrow donation that sounds scary like theyre going to drill into your bone or something," Barr said, noting that it really wasn't as intense of a procedure as some people may think.

In this case, Schneider had to get a series of shots, the stem cells were collected, and then shipped to Boston for Barr, who is now in remission.

Its incredible. Like, I cant even describe. And I know that I would do the same," Barr said.

First, the two communicated communicated through the registry.

"We had been talking back and forth like online since September. I could tell that we would really hit it off," Barr told Action News.

Then, they decided to meet in person at Schneider's mother's house.

Not only do the two now share some of the same DNA, they keep finding other things they have in common.

Like a photo of Barr's cousin, which looks strikingly similar to Schneider.

I look like her! she said, pointing at the photo Barr brought with her.

For both Barr and Schneider, this full-circle experience is a reminder of how important the the Be The Match registry is, for the thousands of people waiting to find their life-saving donor, and just possibly, a life-long connection too.

Barr, who is now a healthy 26-year-old, is working in the health field. She works in the Hemostasis and Thrombosis Division at Beth Israel Deaconess Medical Center (BIDMC), hoping to help others who have been diagnosed with potentially terminal diseases.

Barr said her experience beating Leukemia inspired her to go into the medical field as a biologist to study diseases of the blood.

She is a currently also a volunteer with Be The Match, and conducts her own registry drives as living proof of how important the registry is and how bone marrow donations can save lives.

Click here to join the register or the learn more about the Be The Match.

Go here to read the rest:
News Royal Oak native meets woman she saved with vital stem cell donation Jenn Schanz 11 - WXYZ

UCLA researchers discover new compound that promotes lung health – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise A molecule identified by UCLA researchers helps maintain a healthy balance of cells in airway and lung tissue. If the compound, so far only studied in isolated human and mouse cells, has the same effect in people, it may lead to new drugs to treat or prevent lung cancer.

We think this could help us develop a new therapy that promotes airway health, said Dr. Brigitte Gomperts, a UCLA professor of pediatrics and of pulmonary medicine, a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and lead author of the study. This could not only inform the treatment of lung cancer, but help prevent its progression in the first place.

Humans respiratory systems are constantly being injured by pollution and germs in the air we breathe and must be replenished with healthy cells. That process is driven by airway basal stem cells, which divide to produce both more stem cells and the mucociliary cells that line the airways and lungs.

There are two types of mucociliary cells: mucus cells, which produce the mucus that trap toxic and infectious particles, and ciliated cells, which have finger-like projections that sweep the mucus away to keep the respiratory system healthy and clear. In healthy lungs, airway basal stem cells stay balanced between producing mucociliary cells and self-renewing to maintain a population of stem cells.

In precancerous cells in the lungs, basal stem cells divide more often than usual, generating a large number of stem cells but too few mucociliary cells. The resulting imbalance of cells in the airway leaves the airways unable to properly clear debris, and it creates a greater risk that the precancerous cells will give rise to a tumor.

In the new study, published today in Cell Reports, Gomperts and her colleagues analyzed airway cells from equal numbers of biopsies of healthy people, people with premalignant lung cancer lesions and people with squamous lung cancer. They discovered that one group of molecules collectively called the Wnt/beta-catenin signaling pathway was present at different levels in the basal stem cells of the patient samples versus the cells from healthy people.

And when the researchers altered the levels of these molecules in healthy airway cells from mice, the balance between stem cells and mucociliary cells shifted, mimicking the imbalance seen in lung pre-cancers.

When you activate the Wnt/beta-catenin signaling pathway, these stem cells just divide and divide, said Gomperts, who is also a member of the UCLA Jonsson Comprehensive Cancer Center.

Finally, the team screened more than 20,000 chemical compounds for their ability to reverse this effect in human cells, lowering levels of Wnt and restoring the balance of stem cells and mature airway cells.

One compound stood out for its ability to limit the proliferation of basal stem cells and restore the balance of the stem cells and mucociliary cells to normal. The compound was also less toxic to airway cells than other, previously discovered, molecules that block Wnt/beta-catenin signaling. The team named the compound Wnt Inhibitor Compound 1, or WIC1.

The identification of this new drug is a nice tool to tease apart the biology of the Wnt/beta-catenin signaling pathway and its effects on lung health, said Cody Aros, the first author of the new paper and a UCLA graduate student. Its also very exciting that it may act in a new way than other existing Wnt/beta-catenin signaling pathway inhibitors and has such low toxicity.

Since WIC1 was identified through a random drug screen, the researchers dont yet know exactly how it works, but theyre planning future studies on its mechanism and safety.

The compound tested by the researchers was used in preclinical tests only and has not been tested in humans or approved by the Food and Drug Administration as safe and effective for use in humans.

The newly identified compound is covered by a patent application filed by the UCLA Technology Development Group on behalf of the Regents of the University of California, with Gomperts and Aros as co-inventors.

Funding for the study was provided in part by the National Institutes of Health, the National Cancer Institute, the Tobacco Related Disease Research Program and the Broad Stem Cell Research Center Training Program, including support from the Rose Hills Foundation Graduate Scholarship.

SEE ORIGINAL STUDY

Visit link:
UCLA researchers discover new compound that promotes lung health - Newswise

Family honors the memory of loved one by collecting teddy bears for families dealing with cancer – KTIV

SIOUX CITY (KTIV) - For five years now, the Ruehle family has held a teddy bear drive in memory of Mike Ruehle, who passed from cancer in 2014.

The teddy bears are given to adults and children with a cancer connection, in Mike's memory.

Family and friends knew Mike as "Bear."

The family asks people to consider donating a teddy bear in memory of a loved one, or in honor of healthy family members.

If you'd like to donate, every bear must be new with the tag still attached. The donations will stay in Siouxland.

There are five different locations where you can drop off the bears:

Ruehle's family says the teddy bear drive has donated more than 3,000 stuffed animals to several Siouxland agencies.

But who is the man who inspired the teddy bear drive?

"Very thoughtful person, very giving, he always took the time to listen to other people, just a really compassionate, kindhearted person," said Kerry Ruehle, Mike's Widow.

Mike Ruehle, or as his family called him, Bear, passed away six years ago, after a 12 year battle with cancer.

The family said he was very active in the community and was often coaching numerous sports teams.

They said he had a big heart, and always did what he could to make others feel better, even while he himself had cancer.

"If there were any patients his doctor had, who were having a difficult time with the news or with the adjustment. He would reach out to my dad, and see if my dad would sit down with them and talk about what was going on with them," said Rhett, Mike's son.

Part of the reason the teddy bear drive was started was because of Bear's compassion towards children who were also dealing with cancer.

"He would see a young child going through similar things that he was going through. He would always go out of his way to talk to that little kid and brighten their day a little bit," said Rhett.

Mike had had three different kinds of cancers, and due to the chemotherapy, eventually was diagnosed with MDS, which is a bone marrow failure disorder.

Doctors determined that the best treatment would be a stem cell transplant. The transplant surgery went well, but months later his body began rejecting his brother's stem cells, and within five weeks he had passed away.

"It was a shock because he had been ahead of schedule and everything else. And he had come through things beautifully, so it was quite a shock. But it was god's plan I guess," said Kerry.

But Mike's family wanted a way to keep Mike's memory alive, and that's what also helped start the teddy bear drive.

"My oldest granddaughter is five, she never met her grandpa. But in some ways, she feels as though she did, because of talking about him and she helps me with the bear drive," said Kerry

Original post:
Family honors the memory of loved one by collecting teddy bears for families dealing with cancer - KTIV

Transplanting the immune system: Easier on patients than medication? – WNDU-TV

There are nearly 35,000 organ transplants done in the U.S. every year. Once patients receive their transplant, they face a lifetime of medications that keep their body from rejecting the new organ, but those medications can cause serious side effects.

Now, a groundbreaking procedure has successfully changed that for one woman.

Having breakfast together was nearly impossible for Barb Okey and her husband after her kidney transplant. The 24 pills she took before breakfast ruined her appetite, and the side effects left her tired. But that's all in the past now.

In 27 years doing transplants, Dr. Dixon Kaufman has never done one like Barb's. Her sister's kidney was a perfect match, but then both women took part in a second pioneering transplant to give Barb her sister's immune system.

"We had the transplant and the next day I started radiation. I had to do radiation for 10 days," Barb recalled. "That was to suppress my immune system. After the 10th day, they gave me my sister's stem cells."

"The immune cells start to multiply, so she has not only the kidney from her sister but a little bit of her sister's immune system, and we call that phenomenon chimerism a,nd that's where you have a dual immune system," Kaufman said.

The immunity accepted the new kidney and left Barb drug-free.

"It's the start of hopefully a long progression of trials that will allow more and more people to, if not completely eliminate the medicines, significantly reduce them," Kaufman said.

"I feel very, very lucky. Very lucky," Barb said.

Barb is just the second person in the U.S. to take part in the national trial pioneering the duel transplant. The hope is that the procedure will one day be available to transplant recipients who are not perfect matches with their donors, and possibly even to those who have had transplants in the past.

MEDICAL BREAKTHROUGHSRESEARCH SUMMARYTOPIC: TRANSPLANTING THE IMMUNE SYSTEM: EASIER ON PATIENTS?REPORT: MB #4700

BACKGROUND: Organ transplantation is sometimes necessary when one of a patient's organs has failed. This can happen because of injury or illness. The organ may come from a living donor or one who has died. Transplants can include heart, intestine, kidney, liver, lung, or pancreas. Often patients must wait a long time for an organ transplant and doctors must match donors to recipients to reduce the risk of transplant rejection. (Source: https://medlineplus.gov/organtransplantation.html)

REJECTION RISK: The immune system usually protects you from substances that may be harmful, but it can also simply attack anything that enters the body, which the immune system detects as "foreign", and this includes transplanted organs. When a person receives an organ in transplant surgery, their immune system may recognize that it is foreign if the cells of the organ are different or "not matched". Mismatched organs can trigger a blood transfusion reaction or transplant rejection. To help prevent this rejection, doctors try their best to match similar proteins known as antigens between the donor and recipient. Tissue typing ensures the organ or tissue is as similar as possible to the recipient's tissue. The match is usually not perfect, as only identical twins have identical tissue antigens. Doctors use medicines to suppress the recipient's immune system with the goal of preventing it from attacking the newly transplanted organ. If these medicines are not used, the body will almost always launch an immune response and destroy the foreign tissue. Some exceptions include cornea transplants, because the cornea has no blood supply. Also, transplants from one identical twin to another are almost never rejected. (Source: https://medlineplus.gov/ency/article/000815.htm)

NEW RESEARCH: Medeor Therapeutics is now developing cell-based therapy to reprogram an organ recipient's immune system to accept the transplanted kidney without the need for long-term use of immune system suppressing drugs. The study is in Phase 3 and is working to demonstrate the efficacy and safety of how transplanting some of the stem cells from the organ donor into the organ recipient after transplant surgery could cause an immune tolerance; preserving the organ donation and preventing kidney transplant rejection. It would also eliminate the need for immunosuppressive drugs for the rest of the patient's life. (Source: https://clinicaltrials.gov/ct2/show/study/NCT03363945?show_locs=Y#locn)

Link:
Transplanting the immune system: Easier on patients than medication? - WNDU-TV